RxDoctor Payments Data

William Schoolmeester, MD

Cardiovascular Disease · Camden, SCNPI 1104858950

Payments from drug & device makers

$6,067in general payments, 2019–2025

Across 358 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$822
  • Merck$528
  • Amgen$426
  • Johnson & Johnson$367
  • Pfizer$315
  • Biotronik Inc.$307
  • plus $3K from 30 others

What the payments were for

  • Consulting fees$190%
  • Food & beverage$5,91798%
  • Education$1312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,067 in reported general payments places this provider in the 60th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$455,346
Medicare patients
543
Services billed
5,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban386$353,945
Repatha SureclickEvolocumab158$134,102
EntrestoSacubitril/Valsartan109$121,320
XareltoRivaroxaban105$111,818
JardianceEmpagliflozin21$24,429
Praluent PenAlirocumab24$17,399
Repatha SyringeEvolocumab14$11,698
Ezetimibe195$6,069
Nebivolol Hcl67$6,026
Rosuvastatin Calcium347$5,970
Ranolazine ErRanolazine36$3,826
Atorvastatin Calcium274$3,807
SotalolSotalol Hcl174$3,575
Metoprolol Succinate271$3,429
Valsartan90$3,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$315$353,945386 claims
NovartisEntresto$822$121,320109 claims
Johnson & JohnsonXarelto$367$111,818105 claims
Boehringer IngelheimJardiance$282$24,42921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Camden

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →